Window Will Remain Open for Awhile
Even in a Heated Market IPO Isn't for Every Biotech
By Brian Orelli
Monday, August 5, 2013
With 23 U.S. biotechs going public on U.S. exchanges so far this year, compared to just 11 initial public offerings (IPOs) all of last year, the IPO window is starting to look more like an IPO bubble.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.